
India's Dr Reddy's posts worst week in 3 years as semaglutide setback stokes growth fears
Dr Reddy’s Laboratories logged its steepest weekly loss in three years on Friday, after a disruption in generic semaglutide supply raised concerns it could lose its edge in the highly competitive diabetes market.

































.jpg)










































_20260505133708383_cb6fb9.jpg)

_20260417042625523_ea5c44.jpeg)
_20260611105747709_23ba41.webp)




